# US 2014/0154687 A1 · Apparatus and method for pretreatment of microbial samples

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154687 A1
- Document ID: US20140154687A1
- Status: Published application
- Kind: A1
- Application number: 13/833,872
- Filed: 2013-03-15
- Published: 2014-06-05
- Earliest claimed: 2012-11-30
- Assignees: Qvella Corporation
- Applicants: Qvella Corporation
- Inventors: Samad TALEBPOUR; Aye Aye KHINE; Robert MAASKANT; Tino ALAVIE
- Web page: https://patentgrep.com/patent/US20140154687A1

## CPC

- C12Q 1/6848: characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
- B01L 3/5021: {Test tubes specially adapted for centrifugation purposes}
- B01L 3/5027: {by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip}
- C12Q 1/02: involving viable microorganisms
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- B01L 3/50215: {using a float to separate phases}
- B01L 7/52: {with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples}
- B01L 2200/026: Fluid interfacing between devices or objects, e.g. connectors, inlet details
- B01L 2300/046: Function or devices integrated in the closure
- B01L 2300/0816: Cards, e.g. flat sample carriers usually with flow in two horizontal directions
- B01L 2300/0864: comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
- B01L 2300/1833: using electrical currents in the sample itself
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE

## Abstract

Methods and devices are provided for pretreatment of a sample containing microbial cells. In some embodiments, the pretreatment of the sample is performed via the initial selective lysis, within a sample pretreatment vessel, of non-microbial cells (such as blood cells) and the subsequent centrifugation of the sample to remove the resulting debris and concentrate the microbial cells. An immiscible and dense cushioning liquid may be included, for collecting the microbial cells adjacent to a liquid interface formed by the cushioning liquid, upon centrifugation of the pretreatment vessel. After removal of a substantial quantity of the supernatant, resuspension of the collected microbial cells, and re-establishment of the liquid interface, at least a portion of the remaining suspension may be removed without substantially removing the cushioning liquid. One or more intermediate wash cycles may be performed to prior to extraction of the pretreated sample.

## Claims

### Claim 1

A method of extracting microbial cells from a whole blood sample in a pretreatment vessel,
the pretreatment vessel comprising a pretreatment mixture, the pretreatment mixture comprising:
a blood cell lysis reagent; and
a hydrophobic cushioning liquid having a density greater than that of the whole blood sample and the blood cell lysis reagent;
the method comprising:
adding a whole blood sample to the pretreatment vessel;
agitating the contents of the pretreatment vessel;
centrifuging the pretreatment vessel such that the cushioning liquid forms a liquid interface below a supernatant, wherein microbial cells within from the whole blood sample are removed from suspension and collected adjacent to the liquid interface;
withdrawing a substantial quantity of the supernatant without extracting the collected microbial cells;
agitating the contents of the pretreatment vessel and allowing the cushioning liquid to re-establish the liquid interface below a suspension containing the microbial cells; and
extracting a least a substantial portion of the suspension without extracting a substantial portion of the cushioning liquid.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the volume of cushioning liquid is between approximately 0.1% and 10% of the vessel volume.

### Claim 3 (depends on 1)

The method according to claim 1 wherein prior to agitating the contents of the pretreatment vessel and allowing the cushioning liquid to reestablish the liquid interface below a suspension containing the microbial cells, the following washing steps are performed:
adding a volume of wash buffer to the pretreatment vessel;
agitating the contents of the pretreatment vessel;
centrifuging the pretreatment vessel such that the cushioning liquid forms a liquid interface below a supernatant, and such that microbial cells are transported to and collected at the liquid interface; and
withdrawing a substantial quantity of the supernatant without extracting the collected microbial cells.

### Claim 4 (depends on 3)

The method according to claim 3 further comprising performing the washing steps one or more additional times.

### Claim 5 (depends on 1)

The method according to claim 1 wherein after centrifugation, the liquid interface is formed on a side portion of the pretreatment vessel, wherein the method further comprises re-orienting the pretreatment vessel such that the liquid interface is substantially horizontal, and wherein reorientation of the pretreatment vessel is performed such that a substantial quantity of the microbial cells remain collected at the liquid interface.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the blood cell lysis reagent is an aqueous solution containing saponin in an amount ranging between approximately 1.5 and 80 milligram per milliliter of whole blood and blood cell lysis reagent mixture.

### Claim 7 (depends on 1)

The method according to claim 1 wherein the blood cell lysis reagent further contains sodium polyanetholesulfonate in an amount ranging between approximately 0.5 and 20 mg, per milliliter of whole blood and blood cell lysis reagent mixture.

### Claim 8 (depends on 1)

The method according to claim 1 wherein the blood cell lysis reagent further comprises contains an antifoaming agent.

### Claim 9 (depends on 8)

The method according to claim 8 wherein the antifoaming agent is poly(propylene glycol).

### Claim 10 (depends on 1)

The method according to claim 1 further comprising:
lysing the microbial cells within the extracted suspension to obtain a lysate; and
performing at least one assay to detect at least one analyte that may be present in the lysate.

### Claim 11 (depends on 10)

The method according to claim 10 wherein the step of lysing the microbial cells is performed electrically.

### Claim 12 (depends on 10)

The method according to claim 10 wherein the electrical lysis is performed according to the steps of:
providing a microfluidic device comprising:
a fluidic channel having an upper channel surface, a lower channel surface, a side wall, and a thickness on a submillimeter scale;
an upper electrode on the upper channel surface; and
a lower electrode on the lower channel surface;
wherein the channel is adapted to support flash heating of the extracted suspension under the application of voltage pulses to the electrodes;
flowing the extracted suspension into the channel; and
applying a series of bipolar voltage pulses between the upper electrode and the lower electrode, wherein an amplitude, pulse width, and duration of the voltage pulses are sufficient to flash heat the extracted suspension and irreversibly electroporate the microbial cells, thereby releasing macromolecules from the microbial cells.

### Claim 13 (depends on 10)

The method according to claim 10 wherein at least one of the assays is performed by polymerase chain reaction.

### Claim 14 (depends on 10)

The method according to claim 10 wherein at least one of the assays is performed, at least in part, by reverse transcription polymerase chain reaction.

### Claim 15 (depends on 10)

The method according to claim 10 wherein at least one of the analytes is rRNA.

### Claim 16 (depends on 1)

The method according to claim 1 wherein the microbial cells are bacterial and/or fungal cells.

### Claim 17

A pretreatment vessel for extracting microbial cells from a whole blood sample, comprising:
a vessel body defining an internal volume and an enclosure mechanism for sealing the vessel, wherein the vessel body is configured for use in a centrifugation device, and wherein distal portion of the vessel body is conical in shape;
the vessel body containing:
a pretreatment mixture comprising a blood cell lysis reagent, and
a hydrophobic cushioning liquid having a density greater than that of the whole blood sample and the blood cell lysis reagent, wherein the cushioning liquid forms a liquid interface below a supernatant upon centrifugation of the vessel body such that microbial cells within a whole blood sample are removed from suspension and collected adjacent to the liquid interface;
wherein the cushioning liquid has a volume between approximately 0.1% and 10% of the vessel volume.

### Claim 18 (depends on 17)

The pretreatment vessel according to claim 17 wherein an internal surface of the vessel body is siliconized.

### Claim 19 (depends on 17)

The pretreatment vessel according to claim 17 wherein the blood cell lysis reagent is an aqueous solution containing saponin in an amount ranging between approximately 1.5 and 80 mg, per milliliter of whole blood and blood cell lysis reagent mixture.

### Claim 20 (depends on 17)

The pretreatment vessel according to claim 17 wherein the blood cell lysis reagent further contains sodium polyanetholesulfonate in an amount ranging between approximately 1.5 and 60 mg, per milliliter of whole blood and blood cell lysis reagent mixture.

### Claim 21 (depends on 17)

The pretreatment vessel according to claim 17 wherein the blood cell lysis reagent further contains an antifoaming agent.

### Claim 22 (depends on 21)

The pretreatment vessel according to claim 21 wherein the antifoaming agent is poly (propylene glycol).
